Prof. Dr. med. Winfried Brenner
Director of the Department of Nuclear Medicine
Charité - Universitätsmedizin Berlin
Augustenburger Platz 1
13353 Berlin
Tel: +49 30 450 527 051
Fax: +49 30 450 7 527 051
Email: winfried.brenner(at)charite.de
https://nuklearmedizin.charite.de/metas/person/person/address_detail/brenner-2/
Scientific Scope
Our primary aims are
- Development and in-vivo testing of new radioactive labeled pharmaceuticals for diagnosis and/or treatment of cancer on a preclinical and clinical scale
- Development of new or improved quantitative multimodal imaging approaches including SPECT, PET, CT and MRI for tumor characterization, biokinetic modeling, radiomics and texture analysis including deep learning approaches
- Use of multifunctional imaging procedures as an additional tool for all groups working on in-vivo studies in cancer research in men, mice, CAM, and organoids
So our research within BSIO comprises oncology, (radio)chemistry, and quantitative imaging/physics/radiomics/kinetic modeling.
Name and Position of Group Members
Department of Nuclear Medicine and Berlin Experimental Radionuclide Imaging Center (BERIC)
https://nuklearmedizin.charite.de/
Dr. Sarah Spreckelmeyer – Radiochemist
Dr. Sonal Prasad – Radiochemist, cell cultures
Dr. Nicola Beindorff – veterinarian, board-certified in laboratory animal science
Ajay Mohan, PhD student
Selected References
- Lisec, J., Kobelt, D., Walther, W., Mokrizkij, M., Grötzinger, C., Jaeger, C., Baum, K., Simon, M., Wolf, J., Beindorff, N., Brenner, W., Stein, U.(2021) "Systematic Identification of MACC1-Driven Metabolic Networks in Colorectal Cancer." Cancers (Basel). 13(5):978. doi: 10.3390/cancers13050978.
- Nestle, U., Schimek-Jasch, T., Kremp, S., Schaefer-Schuler, A., Mix, M., Küsters, A., Tosch, M., Hehr, T., Eschmann, S. M., Bultel, Y. P., Hass, P., Fleckenstein, J., Thieme, A., Stockinger, M., Dieckmann, K., Miederer, M., Holl, G., Rischke, H. C., Gkika, E., Adebahr, S., … PET-Plan study group (2020) "Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial."The Lancet Oncology, 21(4), 581–592.
- Rahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M., Essler, M., Baum, R. P., Kulkarni, H. R., Schmidt, M., Drzezga, A., Bartenstein, P., Pfestroff, A., Luster, M., Lützen, U., Marx, M., Prasad, V., Brenner, W., Heinzel, A., Mottaghy, F. M., Ruf, J., … Krause, B. J. (2017) "German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients." Journal of nuclear medicine, 58(1), 85–90.
- von Forstner, C., Egberts, J.H., Ammerpohl, O., Niedzielska, D., Buchert, R., Mikecz, P., Schumacher, U., Peldschus, K., Adam, G., Pilarsky, C., Grutzmann, R., Kalthoff, H., Henze, E., Brenner, W. (2008) "Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in fused PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer." J. Nucl. Med. 49: 1362-1370.
- Aicher*, A., Brenner, W*., Zuhayra, M., Badorff, C., Massoudi, S., Assmus, B., Eckey, T., Henze, E., Zeiher, A. M., & Dimmeler, S. (2003) "Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling." Circulation, 107(16), 2134–2139.